Comparative efficacy and safety of JAK/TYK2 inhibitors and other oral drugs for moderate-to-severe plaque psoriasis: Systematic review and network meta-analysis
Indian Journal of Dermatology, Venereology and Leprology · 2024
DOI: 10.25259/ijdvl_775_2023 ↗Kurz gefasst
Systematische Übersicht in der Zeitschrift Indian Journal of Dermatology, Venereology and Leprology, 2024. Verfasst von Yaxuan Zheng und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Dermatology and Venerology, Fujian Medical University Union Hospital, Fuzhou, China. Hauptthemen laut MEDLINE: Janus Kinase Inhibitors, Psoriasis, Severity of Illness Index, TYK2 Kinase. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 44 Literaturangaben.
Abstract (Originalsprache)
Background
Janus kinase (JAK)/tyrosine kinase 2 (TYK2) inhibitors are novel treatments for moderate-to-severe plaque psoriasis.
Objective
To perform a network meta-analysis to compare the efficacy and safety of TYK2 inhibitors with other oral drugs in moderate-to-severe psoriasis.
Methods
Eligible randomised clinical trials (RCTs) were identified from public databases (published before November 2, 2023). Random-effect frequentist network meta-analysis was performed with ranking based on the surface under the cumulative ranking curve (SUCRA) of Physician’s Global Assessment of “clear” or “almost clear” (PGA 0/1), 75% reduction from baseline in Psoriasis Area and Severity Index (PASI-75).
Results
Twenty RCTs containing 7,564 patients with moderate-to-severe psoriasis were included. Deucravacitinib at all dose levels (except for 3 mg every other day) and tofacitinib (10 mg BID) ranked best in achieving PGA 0/1 and PASI-75 at 12– 16 weeks. Tofacitinib (10 mg BID) was considered the most unsafe. Analysis of Ranking according to efficacy and safety showed deucravacitinib (3 mg QD and 3 mg BID) was the best treatment. Analysis of Ranking according to efficacy and safety showed deucravacitinib (3 mg QD and 3 mg BID) was the best treatment. Limitation Insufficiency of eligible data and no long-term follow-up data.
Conclusion
Deucravacitinib showed superior efficacy and safety for treating moderate-to-severe psoriasis over other included drugs.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Dermatology and Venerology, Fujian Medical University Union Hospital, Fuzhou, China.
Zitieren
APA
Zheng, Y., Han, Y., Chen, J., Huang, J., Zhu, C., Lin, L., & Su, H. (2024). Comparative efficacy and safety of JAK/TYK2 inhibitors and other oral drugs for moderate-to-severe plaque psoriasis: Systematic review and network meta-analysis. Indian Journal of Dermatology, Venereology and Leprology. https://doi.org/10.25259/ijdvl_775_2023
Vancouver
Zheng Y, Han Y, Chen J, Huang J, Zhu C, Lin L, et al. Comparative efficacy and safety of JAK/TYK2 inhibitors and other oral drugs for moderate-to-severe plaque psoriasis: Systematic review and network meta-analysis. Indian Journal of Dermatology, Venereology and Leprology. 2024. doi:10.25259/ijdvl_775_2023
BibTeX
@article{Zheng2024,
author = {Zheng, Yaxuan and Han, Yue and Chen, Jincong and Huang, Jiahao and Zhu, Changhua and Lin, Lihang and Su, Huichun},
title = {Comparative efficacy and safety of JAK/TYK2 inhibitors and other oral drugs for moderate-to-severe plaque psoriasis: Systematic review and network meta-analysis},
journal = {Indian Journal of Dermatology, Venereology and Leprology},
year = {2024},
doi = {10.25259/ijdvl_775_2023}
}
EUVIMED